Details for: JAKAVI
Company: NOVARTIS PHARMACEUTICALS CANADA INC
| DIN | DIN name | Active Ingredient(s) | Strength | Dosage Form | Route of Administration |
|---|---|---|---|---|---|
| 02388006 | JAKAVI | RUXOLITINIB (RUXOLITINIB PHOSPHATE) | 5 MG | TABLET | ORAL |
| 02434814 | JAKAVI | RUXOLITINIB (RUXOLITINIB PHOSPHATE) | 10 MG | TABLET | ORAL |
| 02388014 | JAKAVI | RUXOLITINIB (RUXOLITINIB PHOSPHATE) | 15 MG | TABLET | ORAL |
| 02388022 | JAKAVI | RUXOLITINIB (RUXOLITINIB PHOSPHATE) | 20 MG | TABLET | ORAL |
Summary Reports
Summary Basis of Decision
Regulatory Decision Summary
Summary Safety Review - Ruxolitinib - Assessing the potential risk of liver injury
Summary Safety Review - JAKAVI (ruxolitinib) - Assessing the potential risk of drug interactions with P-glycoprotein (P-gp) substrates (including rosuvastatin)
Summary Safety Review - Xeljanz and Xeljanz XR (tofacitinib) and Jakavi (ruxolitinib) - Janus Kinase (JAK) inhibitors - Assessing the Potential Risk of Blood Clots in the Deep Veins (Venous Thromboembolic Events)
Regulatory Decision Summary
Summary Safety Review - Ruxolitinib - Assessing the potential risk of liver injury
Summary Safety Review - JAKAVI (ruxolitinib) - Assessing the potential risk of drug interactions with P-glycoprotein (P-gp) substrates (including rosuvastatin)
Summary Safety Review - Xeljanz and Xeljanz XR (tofacitinib) and Jakavi (ruxolitinib) - Janus Kinase (JAK) inhibitors - Assessing the Potential Risk of Blood Clots in the Deep Veins (Venous Thromboembolic Events)
Consumer Information
The Consumer Information is not yet available in the Drug and Health Product Register. Try searching on the active ingredient(s) to find other similar products.